Median PFS (BICR) in patients with tumor-cell PD-L1 ≥ 1% was numerically longer in the NIVO + IPI versus the Chemo arm (5.4 vs. 4.2 months); however, the risk of progression or death was comparable between the arms (HR 0.84 [0.54–1.32]) (Fig. 1c). This evidence concerns the gene CD274 and neoplasm.